Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. develops clinical-stage treatments for rare diseases and diseases with high unmet need, with news centered on anti-infective programs for multi-drug resistant bacterial infections. Updates frequently cover tebipenem HBr, an investigational oral carbapenem antibiotic for complicated urinary tract infections, including pyelonephritis, and its licensed development and commercialization relationship with GSK outside certain Asian territories.
Company announcements also report quarterly and annual operating results, business updates, clinical data presentations, FDA submission activity, portfolio-expansion efforts, cash runway commentary, and equity-compensation grants under Nasdaq rules.
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, announced on June 3, 2024, that its Board's Compensation Committee approved the grant of 116,667 restricted stock units (RSUs) under its 2019 Inducement Equity Incentive Plan. The RSUs serve as an inducement for a new employee, in line with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four annual installments starting June 1, 2025, contingent on the employee's continued employment.
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in treatments for rare diseases and multi-drug-resistant bacterial infections, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place on May 20, 2024, at NASDAQ World Headquarters in New York, NY. During the conference, Spero's President and CEO, Sath Shukla, will engage in a fireside chat and one-on-one meetings. The session is scheduled from 1:30 - 2:00 PM ET and will be accessible via webcast on Spero's website, with a replay available post-event.
Spero Therapeutics (Nasdaq: SPRO) reported its Q1 2024 financial results and provided a business update. The company continues advancing its clinical pipeline, with key trials underway. Topline data for SPR720, aimed at treating NTM-PD, is expected in 2H 2024. The Phase 3 trial for tebipenem HBr in cUTI is ongoing, with enrollment completion targeted for 2H 2025. SPR206 received FDA Fast Track designation for HABP/VABP treatment.
Spero reported a net loss of $12.7 million for Q1 2024, a slight improvement from $13.3 million a year ago. Revenue surged to $9.3 million, primarily due to increased collaboration and grant revenues. R&D expenses rose to $17.3 million, reflecting heightened clinical activity. G&A expenses decreased to $5.9 million. The company's cash balance stands at $82.3 million, up from $76.3 million at year-end 2023, bolstered by a $23.8 million milestone payment from GSK. Spero's financial runway is expected to extend into late 2025.
Spero Therapeutics, Inc. (Nasdaq: SPRO) will report its first quarter 2024 financial results and business update on May 15, 2024. The company focuses on developing treatments for rare diseases and MDR bacterial infections.
Spero Therapeutics, Inc. announced the approval of 10,833 restricted stock unit awards to a new employee under the 2019 Inducement Plan. The RSUs will vest in four equal annual installments beginning on May 1, 2025, subject to the employee's continued employment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.